E-LIB Suche - Ergebnisse für: Kragballe, K.

1

Tumour necrosis factor-α plays a significant role in the Al..:

Vinter, H. ; Kragballe, K. ; Steiniche, T....
British Journal of Dermatology. 174 (2016) 5 - p. 1011-1021 , 2016

2

Quality of life and patient benefit following transition fr..:

Augustin, M. ; Blome, C. ; Paul, C....
Journal of the European Academy of Dermatology and Venereology. 31 (2016) 2 - p. 294-303 , 2016

Link: https://doi.org/10.1111/..

3

Transition to ustekinumab in patients with moderate-to-seve..:

Paul, C. ; Puig, L. ; Kragballe, K....
British Journal of Dermatology. 170 (2014) 2 - p. 425-434 , 2014

Link: https://doi.org/10.1111/..

4

Pooled safety analysis of calcipotriol plus betamethasone d..:

Kragballe, K. ; van de Kerkhof, P.
Journal of the European Academy of Dermatology and Venereology. 28 (2014) s2 - p. 10-21 , 2014

Link: https://doi.org/10.1111/..

5

One‐year safety and efficacy of ustekinumab and results of ..:

Reich, K. ; Puig, L. ; Paul, C....
British Journal of Dermatology. 170 (2014) 2 - p. 435-444 , 2014

Link: https://doi.org/10.1111/..

6

Aldara®-induced skin inflammation: studies of patients with..:

Vinter, H. ; Iversen, L. ; Steiniche, T...
British Journal of Dermatology. 172 (2014) 2 - p. 345-353 , 2014

Link: https://doi.org/10.1111/..

7

The expression of dual-specificity phosphatase 1 mRNA is do..:

Kjellerup, R.B. ; Johansen, C. ; Kragballe, K..
British Journal of Dermatology. 168 (2013) 2 - p. 339-345 , 2013

Link: https://doi.org/10.1111/..

8

A consensus report on appropriate treatment optimization an..:

Mrowietz, U. ; de Jong, E.M.G.J. ; Kragballe, K....
Journal of the European Academy of Dermatology and Venereology. 28 (2013) 4 - p. 438-453 , 2013

Link: https://doi.org/10.1111/..

9

Barriers to the prescription of systemic therapies for mode..:

Nast, A. ; Mrowietz, U. ; Kragballe, K....
Archives of Dermatological Research. 305 (2013) 10 - p. 899-907 , 2013

Link: https://doi.org/10.1007/..

10

An assessment of adalimumab efficacy in three Phase III cli..:

Mrowietz, U. ; Kragballe, K. ; Reich, K....
British Journal of Dermatology. 168 (2012) 2 - p. 374-380 , 2012

Link: https://doi.org/10.1111/..

11

PSS28 Long-Term Improvement in Patient-Reported Outcomes Af..:

Reich, K. ; Puig, L. ; Luger, T....
Value in Health. 15 (2012) 7 - p. A573 , 2012

Link: https://doi.org/10.1016/..

12

Factors impacting the combination of topical corticosteroid..:

van de Kerkhof, P.C.M. ; Kragballe, K. ; Segaert, S...
Journal of the European Academy of Dermatology and Venereology. 25 (2011) 10 - p. 1130-1139 , 2011

Link: https://doi.org/10.1111/..

13

PSS21 Treatment Patterns, Costs and Quality of Life in Pati..:

Ragnarson tennvall, G. ; Hjortsberg, C. ; Gniadecki, R....
Value in Health. 14 (2011) 7 - p. A505 , 2011

Link: https://doi.org/10.1016/..

14

Dimethylfumarate inhibits MIF-induced proliferation of kera..:

Gesser, B. ; Rasmussen, M. K. ; Raaby, L....
Inflammation Research. 60 (2011) 7 - p. 643-653 , 2011

Link: https://doi.org/10.1007/..

15

Comparison of drug survival rates for adalimumab, etanercep..:

Gniadecki, R. ; Kragballe, K. ; Dam, T.N..
British Journal of Dermatology. 164 (2011) 5 - p. 1091-1096 , 2011

Link: https://doi.org/10.1111/..